WO2004041292A3 - C-type lectin binding molecules, identification and uses thereof - Google Patents

C-type lectin binding molecules, identification and uses thereof Download PDF

Info

Publication number
WO2004041292A3
WO2004041292A3 PCT/NL2003/000781 NL0300781W WO2004041292A3 WO 2004041292 A3 WO2004041292 A3 WO 2004041292A3 NL 0300781 W NL0300781 W NL 0300781W WO 2004041292 A3 WO2004041292 A3 WO 2004041292A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
type
binding
type lectin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2003/000781
Other languages
French (fr)
Other versions
WO2004041292A2 (en
Inventor
Teunis Bernard Her Geijtenbeek
Kooyk Yvette Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Amsterdam
Original Assignee
Vrije Universiteit Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Amsterdam filed Critical Vrije Universiteit Amsterdam
Priority to AU2003279623A priority Critical patent/AU2003279623A1/en
Priority to DK03772961.3T priority patent/DK1569660T3/en
Priority to US10/533,981 priority patent/US8309097B2/en
Priority to EP03772961.3A priority patent/EP1569660B1/en
Priority to ES03772961.3T priority patent/ES2554355T3/en
Publication of WO2004041292A2 publication Critical patent/WO2004041292A2/en
Publication of WO2004041292A3 publication Critical patent/WO2004041292A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type of carbohydrate bound. In the present invention new carbohydrate specificities of C-type lectins are disclosed. Interference with this binding property has uses in the prevention of pathogen binding and also in influencing signaling pathways in the C-type lectin containing cell, particularly in Toll like receptor expressing cells such as dendritic cells. Also provided is the use of the carbohydrate specificity to enhance antigen presentation by antigen presenting cells and to manipulate migration of C-type lectin containing cells and the interaction of C-type lectin expressing cells with cellular ligands on neighboring cells.
PCT/NL2003/000781 2002-11-07 2003-11-07 C-type lectin binding molecules, identification and uses thereof Ceased WO2004041292A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003279623A AU2003279623A1 (en) 2002-11-07 2003-11-07 C-type lectin binding molecules, identification and uses thereof
DK03772961.3T DK1569660T3 (en) 2002-11-07 2003-11-07 C-TYPE LECTIN BINDING MOLECULES, IDENTIFICATION AND APPLICATIONS THEREOF.
US10/533,981 US8309097B2 (en) 2002-11-07 2003-11-07 C-type lectin binding molecules, identification and uses thereof
EP03772961.3A EP1569660B1 (en) 2002-11-07 2003-11-07 C-type lectin binding molecules, identification and uses thereof
ES03772961.3T ES2554355T3 (en) 2002-11-07 2003-11-07 Type C lectin binding molecules, identification and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02079665A EP1417965A1 (en) 2002-11-07 2002-11-07 C-type lectin binding molecules, identification and uses thereof
EP02079665.2 2002-11-07

Publications (2)

Publication Number Publication Date
WO2004041292A2 WO2004041292A2 (en) 2004-05-21
WO2004041292A3 true WO2004041292A3 (en) 2004-07-29

Family

ID=32103982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000781 Ceased WO2004041292A2 (en) 2002-11-07 2003-11-07 C-type lectin binding molecules, identification and uses thereof

Country Status (9)

Country Link
US (1) US8309097B2 (en)
EP (2) EP1417965A1 (en)
AU (1) AU2003279623A1 (en)
CY (1) CY1117093T1 (en)
DK (1) DK1569660T3 (en)
ES (1) ES2554355T3 (en)
HU (1) HUE025582T2 (en)
PT (1) PT1569660E (en)
WO (1) WO2004041292A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200328B1 (en) 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
SE9904581D0 (en) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and its use
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
AU2011211337B2 (en) * 2003-10-16 2014-10-02 Cancure Limited Immunomodulating compositions and uses therefor
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
US20090155267A1 (en) * 2005-02-09 2009-06-18 Apollo Life Sciences Limited Molecule and chimeric molecules thereof
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2007089133A1 (en) * 2006-02-03 2007-08-09 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing interactions between dc-sign and dc-sign ligands
AT503387B1 (en) * 2006-03-27 2008-05-15 Univ Wien PHARMACEUTICAL COMPOSITION FOR PREVENTING INFECTIONS
WO2008007941A1 (en) * 2006-07-10 2008-01-17 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Gainac specific binding molecules and uses thereof
WO2009132130A2 (en) * 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
CN102947341B (en) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 Engineered opsonins for pathogen detection and treatment
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN104284984B (en) 2012-02-29 2017-10-13 哈佛大学校长及研究员协会 Rapid Test for Antibiotic Susceptibility
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
GB202105804D0 (en) * 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
WO1998039027A2 (en) * 1997-03-05 1998-09-11 John Wayne Cancer Institute Sialyl lewis antigens as targets for immunotherapy
DE69834808T2 (en) * 1997-03-27 2007-06-06 Institut Pasteur MULTIPLE, CARBOHYDRATE-CONTAINING GLYCOPEPTIDE ANTIGENS, VACCINES DEVELOPED THEREFROM AND THEIR USE
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
AU2001231204A1 (en) * 2000-01-27 2001-08-07 Sidney Kimmel Cancer Center Genetically engineered tumor cell vaccines
US6949629B2 (en) * 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLAUDIUS ET AL.: "KINETIC AND EQUILIBRIUM CHARACTERIZATION OF INTERACTIONS BETWEEN GLYCOPEPTIDE ANTIBIOTICS AND SODIUM CARBOXYETHYL STARCH", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 144, 1996, pages 71 - 79, XP002239678 *
FEINBERG ET AL.: "STRUCTURAL BASIS FOR SELECTIVE RECOGNITION OF OLIGOSACCARIDES BY DC-SIGN AND DC-SIGNR", SCIENCE, vol. 294, 7 December 2001 (2001-12-07), pages 2163 - 2166, XP002239677 *
MUTO ET AL.: "BIOLOGICAL ACTIVITIES OF HUMAN MANNOSE-BINDING LECTIN BOUND TO 2 DIFFERENT LIGAND SUGAR STRUCTURES, LEWIS A AND LEWIS B ANTIGENS AND HIGH-MANNOSE TYPE OLIGOSACCARIDES", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1527, 2001, pages 39 - 46, XP002239681 *
SCHOFIELD ET AL.: "SYNTHETIC GPI AS A CANDIDATE ANTI-TOXIC VACCINE IN A MODEL OF MALARIA", NATURE, vol. 418, 15 August 2002 (2002-08-15), pages 785 - 789, XP002239679 *
YAMAMOTO, KAZUO ET AL: "Interaction of Immobilized Recombinant Mouse C-Type Macrophage Lectin wit Glycopeptides and Oligosaccharides", BIOCHEMISTRY (1994), 33(26), 8159-66, 1994, XP002239680 *

Also Published As

Publication number Publication date
DK1569660T3 (en) 2015-12-07
EP1569660B1 (en) 2015-08-26
AU2003279623A8 (en) 2004-06-07
AU2003279623A1 (en) 2004-06-07
PT1569660E (en) 2015-12-07
US8309097B2 (en) 2012-11-13
EP1417965A1 (en) 2004-05-12
HUE025582T2 (en) 2016-04-28
EP1569660A2 (en) 2005-09-07
US20060104975A1 (en) 2006-05-18
ES2554355T3 (en) 2015-12-18
CY1117093T1 (en) 2017-04-05
WO2004041292A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
WO2004041292A3 (en) C-type lectin binding molecules, identification and uses thereof
WO2006085938A3 (en) Il-13 binding agents
MA30153B1 (en) ANTI-OX40L ANTIBODIES AND CORRESPONDING METHODS
WO2006004663A3 (en) Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
WO2004085989A3 (en) Dye compositions which provide enhanced differential fluorescence and light scatter characteristics
PL322681A1 (en) Cytostatic agents modified with carbohydrates
WO2003074548A3 (en) Phage ligand sensor devices and uses thereof
WO2006138457A3 (en) Isolating chip-to-chip contact
WO2001061099A8 (en) Laundry additive sachet
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2001096565A3 (en) Binding agents: chimeric ligand/receptor proteins
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
TW200704927A (en) Mass spectrometric analysis of ligand conjugated magnetic nanoparticles
WO2004046188A3 (en) Anti-activated ras antibodies
AR044847A1 (en) MARMOLATED CUBES TO PREPARE CONSOME, SOIL, SOUP, SAUCE OR SAZONADORES AND PROCEDURE FOR PREPARATION
WO2003057715A3 (en) Novel ligand involved in the transmigration of leukocytes .
WO2007115663A3 (en) Security element
WO2005059517A3 (en) Toll-like receptor assays
WO2001077292A3 (en) Novel signal transduction molecules
WO2007079808A3 (en) Housing for screening from electromagnetic interferences
WO2005079515A3 (en) Conformation specific antibodies
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
ATE478125T1 (en) REVERSIBLE THERMOCHROMIC COMPOSITIONS
WO2003048729A3 (en) Discovery of therapeutic products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1293/CHENP/2004

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003772961

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003772961

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006104975

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10533981

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10533981

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP